Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 25Neoplasms 14Colorectal Neoplasms 14Melanoma 12Carcinoma, Renal Cell 11Neoplasm Metastasis 9Solid Tumors 8Carcinoma, Hepatocellular 8Head and Neck Neoplasms 7Urinary Bladder Neoplasms 6Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 6Ovarian Neoplasms 6Lung Neoplasms 6Carcinoma, Transitional Cell 6Breast Neoplasms 6Uterine Cervical Neoplasms 5Lymphoma 5Kidney Neoplasms 4Endometrial Neoplasms 4Solid Tumor 3Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Advanced Solid Tumors 3Urologic Neoplasms 2Treatment-Refractory Solid Tumors 2Solid Cancers 2Recurrence 2

Interventions

Lenalidomide 3PVX-410 vaccine 2siltuximab 1sargramostim 1poly ICLC 1dexamethasone acetate 1dexamethasone 21-phosphate 1citarinostat 1auricularum 1atezolizumab 1Receptors, Interleukin-6 1Monatide (IMS 3015) 1Interleukin 1 Receptor Antagonist Protein 1Emulsions 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Smoldering Multiple Myeloma × atezolizumab × Clear all
NCT02784483 2020-03-03

Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

Yale University

Phase 1 Terminated
2 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡